Panakeia ("the Company"), the world's first in silico multi-omics company, today unveiled landmark pathway activation data in cancers at the American Association for Cancer Research (AACR) Annual ...
Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...
The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...
Promising Late-Stage Drugs Signal A New Treatment Era Delveinsight. The generalized myasthenia gravis treatment pipeline ...
Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a ...
Immunoglobulin A (IgA) nephropathy results from the accumulation of IgA-containing immune complexes (IgA-ICs) and aberrant IgA antibodies in the glomerular mesangium. Now, researchers have found that ...
Massive hepatic necrosis (MHN) represents the most severe pathological form of acute liver failure (ALF), with high mortality ...
Longhorn Vaccines and Diagnostics (LHNVD), an IND enabling-stage biopharmaceutical company, today announced it will present new preclinical data demonstrating that DRG5--BD11, a novel human bispecific ...
Therapeutic fasting offers a metabolic approach to chronic pain by shifting to fat metabolism, reducing systemic inflammation ...
NIQ (NYSE: NIQ), a leading consumer intelligence company, and Stirista, a provider of identity-driven marketing solutions, ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced preclinical data highlighting an ...
Systemic lupus erythematosus (SLE) involves ongoing inflammation, tissue damage from immune complexes, and incomplete immune resolution. A key factor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results